Please wait a minute...
European Journal of Gynaecological Oncology  2019, Vol. 40 Issue (4): 543-546    DOI: 10.12892/ejgo4546.2019
Original Research Previous articles | Next articles
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent mucinous cystadenoma of the ovary
F. El-Sharkawy1, M. Sittig1, C. Nieroda1, A. Sardi1, *()
1 The Institute for Cancer Care, Mercy Medical Center, Weinberg Building, Baltimore, MD, USA
Download:  PDF(370KB)  ( 174 ) Full text   ( 6 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Purpose: Mucinous cystadenomas (MCA) of the ovary may lead to multiple complications and become recurrent. This study presents the management and long term follow-up of three patients with recurrent ovarian MCA treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Materials and Methods: A retrospective review of a prospective database of 675 patients treated with CRS/HIPEC at a single institution was conducted. Of 132 patients with gynecological tumors, three patients with recurrent ovarian MCA were identified. CRS/HIPEC was performed with 40 mg of mitomycin-C for 90 minutes. Follow-up for disease recurrence was carried out with computed tomography. Results: All patients with recurrent ovarian MCA had a total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH/BSO) as the initial intervention. Two patients recurred twice after the initial procedure and one patient had three recurrences. At the time of CRS/HIPEC, all patients had multiple organ involvement and urinary complications, which resolved after CRS/HIPEC. There were no further recurrences after CRS/HIPEC. Follow-up after CRS/HIPEC was 12, 60, and 72 months. Conclusion: The present authors’ experience shows that CRS/HIPEC is a feasible and effective treatment for recurrent MCA of the ovary in selected patients.
Key words:  Cytoreductive surgery      Hyperthermic intraperitoneal chemotherapy      Mucinous cystadenoma      Ovarian tumor      Recurrence     
Published:  10 August 2019     
*Corresponding Author(s):  A. SARDI     E-mail:  asardi@mdmercy.com

Cite this article: 

F. El-Sharkawy, M. Sittig, C. Nieroda, A. Sardi. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent mucinous cystadenoma of the ovary. European Journal of Gynaecological Oncology, 2019, 40(4): 543-546.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo4546.2019     OR     https://ejgo.imrpress.com/EN/Y2019/V40/I4/543

[1] Jisu Yeom, Seulki Lee, Youngsun Kim. Hypercalcemia associated with primary mucinous ovarian tumor followed by pseudomyxoma peritonei can be fatal: a case report[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 824-827.
[2] T. Uehara, A. Mitsuhashi, M. Shozu. The impact of pre-existing polycystic ovary syndrome on endometrial cancer recurrence[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 668-674.
[3] Adrius Gaurilcikas, Migle Gedgaudaite, Saulius Paskauskas, Tomas Birzietis, Daiva Vaitkiene. Unusual case of Krukenberg tumors diagnosed in early pregnancy[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 806-809.
[4] Silvia Ortega, José Angel Mínguez, José Manuel Aramendía, Marta Santisteban, Fernando Martinez-Regueira, Pablo Martí-Cruchaga, Juan Luis Alcázar, Matías Jurado. The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 523-530.
[5] Sigit Purbadi, Gregorius Tanamas, Lisa Novianti. Advanced stage ovarian cancer survival in Jakarta[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 587-590.
[6] S.R Oh, J.-W. Park. Is the Risk of Malignancy Index a predictive tool for preoperative differentiation between borderline ovarian tumor and ovarian cancer?[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 368-374.
[7] T. Armeanu, R. Maftei, G. Simionescu, D. Nicolaiciuc, N. Plopa, B. Doroftei. Infertility and borderline malignant ovarian tumors: a case of successful pregnancy after fertility-preserving management of the disease[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 284-288.
[8] Y. S. Lee, J. M. Baek, E. K. Park, C. J. Kim, H. J. Lee, J. O. Kim. Expression and therapeutic potential of macrophage migration inhibitory factor and CD74 in ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 65-69.
[9] Z. Xu, H. Wen, Q. Xue. Successful pregnancy achieved by in vitro fertilization after fertility-preserving treatments in an infertile woman with borderline ovarian tumor and endometrial complex atypical hyperplasia: a case report[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 126-129.
[10] Z. Zheng, Z.H. Han, Z.T. Li, X.H. Wu. The impact of laparoscopic surgical treatments on oncologic outcome of Stage I uterine leiomyosarcoma[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 977-981.
[11] R. Tinelli, S. Guicciardini, S. Uccella, E. Cicinelli, F. Romano, G. Trojano. A rare case of false positive metastatic nodes detected at PET/CT scan six months after the laparoscopic treatment of a patient with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1039-1040.
[12] L. N. Abaid, N. Zekry, A. Ronaghi, R. C. Kankus, B. H. Goldstein. Primary management of an extremely large, invasive mucinous ovarian adenocarcinoma: a case report[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1044-1046.
[13] F.V. Carvalho Sousa Esteves, L.A. Gomes de Sousa, R.S. Martins, A.L. Ramos Bezerra de Alencar, L. de Deus Sousa, M.C. Cronemberger Guimarães Serzedo, I. Meneses de Carvalho Coelho, S.C. Vieira. Paget’s disease of the breast after nipple-areola sparing mastectomy: case report[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1087-1090.
[14] N. Kosaka, K. Hasegawa, K. Kiuchi, S. Ochiai, E. Motegi, I. Fukasawa. Two cases of recurrent small-cell carcinoma of the uterine cervix treated with amrubicin as salvage chemotherapy[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1100-1103.
[15] S. Bertozzi, A. P. Londero, S. Bernardi, C. Cedolini. Applicability of the Notthingham Prognostic Index for predicting the survival of triple-negative invasive breast cancer in a single Italian center[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 787-790.
No Suggested Reading articles found!